RT @datsunian: @md_arianemacedo @linfopedia All theoretical interactions thanks to ibrutinib metabolizing glycop & cyp3a4, out of 4 DOACs c…
@md_arianemacedo @linfopedia All theoretical interactions thanks to ibrutinib metabolizing glycop & cyp3a4, out of 4 DOACs could try edoxaban bc of minimal cyp effects. But again it’s all theoretical...would ❤️ registry data on large scale. See @Dr_Mik
RT @datsunian: Great to see wave of literature about AC strategies in cancer patients with their nuances and complexities. See #cardioonc r…
RT @datsunian: Great to see wave of literature about AC strategies in cancer patients with their nuances and complexities. See #cardioonc r…
Great to see wave of literature about AC strategies in cancer patients with their nuances and complexities. See #cardioonc review article by @Dr_Mike_Fradley et al on Anticoagulation of CV Conditions in the Cancer Patient https://t.co/irfJX3kiCx @CardioOnc
RT @Office_j: 【雑記】Curr Oncol Rep誌に、がん患者に対する抗凝固療法についてのレビュー。AF例におけるOAC要否判断に、CHADS2、 CHA2DS2-VAScスコアは必ずしも適切ではないとする。 https://t.co/d2EWbHA6NP
【雑記】Curr Oncol Rep誌に、がん患者に対する抗凝固療法についてのレビュー。AF例におけるOAC要否判断に、CHADS2、 CHA2DS2-VAScスコアは必ずしも適切ではないとする。 https://t.co/d2EWbHA6NP